Enfusion, Inc. (ENFN)
Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Enfusion, Inc. (“Enfusion”) (NYSE: ENFN) and Clearwater Analytics. Investors who purchased Enfusion and continue to hold to the present are encouraged to obtain additional information and assist the investigation.
Investigation Details
The investigation concerns whether Enfusion’s board of directors breached its fiduciary duties and failed to provide relevant information to its shareholders before the merger.
On January 13, 2025, Enfusion announced that it would be acquired by Clearwater Analytics in a cash and stock deal valued at $1.5 billion.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Enfusion shares, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com